{"DataElement":{"publicId":"5235611","version":"1","preferredName":"EGFR vIII Test Percent IHC Result Percentage","preferredDefinition":"Numeric percentage value of EGFR vIII staining by immunohistochemical (IHC) methods.","longName":"EGFRVIII_RSL_PCT_VAL","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"5235326","version":"1","preferredName":"EGFR vIII Test Percent IHC Result","preferredDefinition":"The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor._Genetic alterations found in the neoplastic lesions of the animal model. These alterations are not made intentionally._A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","longName":"5235318v1.0:5235324v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"5235318","version":"1","preferredName":"Epidermal Growth Factor Receptor Mutation","preferredDefinition":"The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor.:Genetic alterations found in the neoplastic lesions of the animal model. These alterations are not made intentionally.","longName":"C17068:C16885","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermal Growth Factor Receptor","conceptCode":"C17068","definition":"Epidermal growth factor receptor (1210 aa, ~134 kDa) is encoded by the human EGFR gene. This protein plays a role in cell-cell adhesion, cell migration, cell proliferation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mutation","conceptCode":"C16885","definition":"Genetic alterations found in the neoplastic lesions of the animal model. These alterations are not made intentionally.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31682F0F-78BA-F3C4-E050-BB89AD4368EC","latestVersionIndicator":"Yes","beginDate":"2016-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-26","modifiedBy":"ONEDATA","dateModified":"2016-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5235324","version":"1","preferredName":"Percent Unit Immunohistochemistry Staining Method Outcome","preferredDefinition":"A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).:Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.:The result of an action.","longName":"C48570:C23020:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percent Unit","conceptCode":"C48570","definition":"A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31682F0F-78F1-F3C4-E050-BB89AD4368EC","latestVersionIndicator":"Yes","beginDate":"2016-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-26","modifiedBy":"ONEDATA","dateModified":"2016-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435027","version":"1","preferredName":"Gene","preferredDefinition":"A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).","longName":"C16612","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB05-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31682F0F-7902-F3C4-E050-BB89AD4368EC","latestVersionIndicator":"Yes","beginDate":"2016-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2434147","version":"1","preferredName":"Percentage Integer","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator._A number with no fractional part.","longName":"2434147v1","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"0","maxLength":"3","minValue":"0","maxValue":"100","decimalPlace":null,"format":"%","PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2434146","version":"1","preferredName":"Percentage Integer","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A number with no fractional part.","longName":"C25613:C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E16DD-4FA5-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E16DD-4FA6-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"COOPERM","dateModified":"2016-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"EGFR vIII IHC % staining","type":"Preferred Question Text","description":"EGFR vIII IHC % staining","url":null,"context":"DCI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31748427-1F94-97FA-E050-BB89AD437EBC","latestVersionIndicator":"Yes","beginDate":"2016-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-27","modifiedBy":"MAESKEB","dateModified":"2016-04-27","changeDescription":"Curated to support Duke University clinical trial. 4.26.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}